A Phase 2 interventional study of Stillen® Tab and Stillen® Tab Placebo in Acute Gastritis and Chronic Gastritis, sponsored by Dong-A ST Co., Ltd.. Completed at 1 site in South Korea. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-08-29.
Sponsored by Dong-A ST Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Gastritis with a site in Korea, Republic of — 3 open to participants now, 3 under way, none of them phase 3. Gastritis · Korea, Republic of.
Among the 32 studies in Gastritis with a site in Korea, Republic of, this one is the 16th largest by enrollment of the 25 interventional ones that give a count, is the only one that started in 1997, is one of 4 in phase 2, and was the 31st registered.
135 studies on the registry are indexed under Gastritis; 23 are open to participants now.
Browse Gastritis studies →3 of the 32 studies in Gastritis with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Daewoong Pharmaceutical Co. LTD. · Sites in Korea, Republic of
Ages 19–75
Korea Otsuka Pharmaceutical Co., Ltd. · Sites in Korea, Republic of
Ages 19+
Addpharma Inc. · Sites in Korea, Republic of
Ages 19–50 · Healthy volunteers
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 11 Gastritis studies recruiting now, 6 (55%) set no upper age limit and 5 (45%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 1 started in 1997.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 212 is close to the median of 200 across 97 interventional studies indexed under Gastritis.
Median enrollment 242 across the 25 interventional studies, 585 across the 7 observational. Of the 23 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 32 have an industry lead sponsor. The 10 most frequent:
Dong-A ST Co., Ltd. is the lead sponsor of 122 studies on the registry; 9 are open to participants now.
Dong-A ST Co., Ltd. has 4 studies filed under Gastritis — fewer than ten, so there is no comparison to draw.
1 of the studies in Gastritis with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07717775Addpharma Inc.A Study of Compare the Pharmacokinetic, Pharmacodynamic and Safety/Tolerability Characteristics Following Multiple Oral Administration of AD-234, AD-2341, and AD-2342 in Healthy Adults | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 32 studies in Gastritis with a site in Korea, Republic of, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multicenter, placebo-controlled, randomized, double-blinded, paralleled group clinical study to evaluate the efficacy of 2-week treatment with DA-9601 tab in patients with acute or chronic gastritis. Subject will receive DA-9601 180mg, 360mg tab or Placebo., three times a day for two weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with peptic ulcer (excluding scars) and reflux esophagitis
Patients who were administered with H2 antagonist, muscarine receptor antagonist or nonsteroidal anti-inflammatory drug within 2 weeks prior to the start of the trial
Patients using protective agent enhancers at the start of the trial ④ Patients with recurrence observed during maintenance therapy at the start of the trial
Patients with a history of gastrectomy
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
administered 2 tablets of placebo three times daily for two weeks
Drug: Stillen® Tab Placebo
administered 1 tablet of placebo and 1 tablet of DA-9601(Stillen®) three times daily for two weeks
Drug: Stillen® Tab · Drug: Stillen® Tab Placebo
administered 2 tablets of DA-9601(Stillen®) three times daily for two weeks
Drug: Stillen® Tab
Oral administration 3 times per day (in-between meals and before sleep) for 2 weeks
Oral administration 3 times per day (in-between meals and before sleep) for 2 weeks
Change in Subjective and Objective Symptoms, Gastroscopy, Overall Improvement, Effectiveness grade
evaluated in 5 levels of "Significant improvement • Moderate improvement • Mild improvement • No improvement • Exacerbation"
Time frame: 2 weeks
Ran from Mar 1997 to primary completion in Jul 1999, 27 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.